

OMTN, Volume 24

Supplemental information

**Advancing peptide siRNA-carrier designs
through L/D-amino acid stereochemical
modifications to enhance gene silencing**

Charles E. Holjencin, Colton R. Feinberg, Travis Hedrick, Gregory Halsey, Robert D. Williams, Priya V. Patel, Evan Biles, James C. Cummings, Chance Wagner, Naren Vyavahare, and Andrew Jakymiw

SUPPLEMENTAL INFORMATION

Supplemental Figures & Legends




Figure S1. Assessment of cytotoxicity after treatment of cancer cells with 599 or its peptide variants in complex with siRNA in comparison to untreated cells. The long-term cellular toxicity (as measured by a cell proliferation assay) of CAL 27 cancer cells was assessed 48 hours post-treatment with 599 or its peptide variants in complex with a non-targeting siRNA (siNT) at 50:1 Peptide:siRNA molar (12.5 N/P) ratios. Untreated cells were defined as 100% viable. Data are mean \pm SEM of three independent samples, where $P \geq 0.05$ is not significant (ns) compared to untreated cells (one-way ANOVA).

Supplemental Tables

Table S1. Raw data from siRNA binding assays. Please see accompanying Excel file for details.

Table S2. Raw data from siRNA release assays. Please see accompanying Excel file for details.